Research Article
Frequency of Serotonin Transporter Promote Gene Polymorphism in Opioid Addicts
Tahere Nazari1, Nasrin Ghasemi2 and Amir Hossein Mansourabadi3*1International Campus, Shahid Sadoughi University of Medical Sciences, Iran
2Research and Clinical, Centre for Infertility, Shahid Sadoughi University of Medical Sciences, Iran
3Immunology department, Shahid Sadoughi University of Medical Science, Iran
- Corresponding Author:
- Amir Hossein Mansourabadi
Immunology Department
Shahid Sadoughi University of Medical Science, Iran
Tel: 09380097059
E-mail: a.mansourabadi.67@gmail.com
Received date: Jan 23, 2016; Accepted date: Apr 15, 2016; Published date: Apr 21, 2016
Citation: Nazari T, Ghasemi N, Mansourabadi A (2016) Frequency of Serotonin Transporter Promote Gene Polymorphism in Opioid Addicts. J Addict Res Ther 7: 278. doi:10.4172/2155-6105.1000278
Copyright: © 2016 Nazari T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Background: The human serotonin transporter promoter (5-HTT) gene genotype was previously reported to be associated with temperament and personality traits at risk for substance abuse in the subjects with antisocial behaviour. Association studies of polymorphism in the promoter region of this gene in addiction have shown conflicting results. A common 44-base pair insertion/deletion polymorphism in the region of 5-HTT has been observed. This biallelic functional polymorphism designated long (L) and short (S) promotors, which affect 5-HTT gene expression since the short variant is associated with lower transcriptional activity. Since there is strong evidence of a disturbance in brain serotonergic transmission among antisocial, impulsive, anxiety, and different kinds of addiction, the purpose of present study was to evaluate the frequency of these genotypes among adolescents with opioid addiction.
Method: One hundred and forty opium dependent males, aged 20-50 years, entered the study, after signing informed written consent. They referred to the rehabilitation centre to treat their addiction. Three questionnaires, general, Minnesota Multiphasic Personality Inventory (MMPI), genetic and family pedigree) were filled out by experts. Information obtained from these questionnaires included their age, gender, consanguinity of parents, type of substance abuse, socioeconomic position, psychiatric disorder and family history of drug abuse and any other diseases. First, behavioural disorders were studied in addict cases. Then, polymorphic region of the human serotonin transporter gene was evaluated and compared between 31 addicts and 31 normal volunteer matched in age, sex and socioeconomic situation as controls. Whole blood sample (2ml) from each participant was collected on sterile tube and stored for subsequent extraction of DNA using phenol-chloroform method. Then DNA was PCR-amplified. The PCR products were resolved in 2.5% agarose gel. Data were analysed using chi-square test and P < 0.05 was considered significant.
Results: Short allele frequency in cases and controls were 0.532 and 0.387 respectively. Long allele frequency in cases and control were 0.468 and 0.613 respectively. Despite of OR =1.8 this study indicate no significant association between frequency of short allele and addiction to opioid.
Conclusions: Although previous findings indicated association of short allele with addiction, this study did not confirm these results. Several possibilities exist for these discrepant results, including small sample size, potential population stratification, and categorical phenotypes.
